How semaglutides help you lose weight — and what that means for you

What semaglutide actually does inside your body

Your gut releases a hormone called glucagon-like peptide-1 (GLP-1) after you eat. It tells your pancreas to release insulin, signals your brain that you are full, and slows the movement of food through your stomach. In people with obesity, this system often works less effectively, the fullness signal arrives late or too weakly, and hunger returns sooner than it should.

Semaglutide is a synthetic version of GLP-1, engineered to last much longer in the body than the natural hormone. A weekly injection of Wegovy keeps GLP-1 receptors active continuously rather than briefly after meals. If you want to understand how Wegovy helps you lose weight by working on these receptors and appetite signals, the dedicated page walks through the mechanism in plain terms. This is not a willpower fix. It is a pharmacological correction of a biological signal. For a fuller look at the physiological detail, the full explanation of how semaglutides cause weight loss goes deeper into the receptor pathway.

Semaglutide in its weekly injection form is sold as Wegovy for weight management and as Ozempic for type 2 diabetes. They contain the same molecule at different doses; only Wegovy is licensed for weight loss in the UK. The distinction matters, and it is one our overview of semaglutide covers clearly.

What the trial results show, and what they do not

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity or overweight plus at least one weight-related condition for 68 weeks. Those on semaglutide 2.4 mg lost around 15% of body weight on average; those on placebo lost around 2.4%. That gap is clinically significant, and it held even when the analysis accounted for people who did not complete the trial.

A few things the trial does not tell you are equally worth knowing. Participants also received lifestyle support, reduced-calorie guidance and activity coaching. The medicine works alongside those changes, not instead of them. Results also varied: some people lost considerably more than 15%, others less. Biology, starting weight, how consistently the treatment was taken, and how well gastrointestinal side effects were managed all play a role.

One practical habit worth building early: before each new pen, check that the liquid is clear and colourless. A cloudy or discoloured solution should not be injected, it takes under a minute to look, and it is the kind of check the Patient Information Leaflet asks you to do every time.

The question of whether semaglutide will help you specifically is a different one, and it is ultimately answered by a prescriber who can see your full health picture, not by a population average.

Who the licence covers, and who needs to think carefully

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, a prescriber will work through this with you. The Wegovy treatment page sets out the eligibility criteria in full.

There are situations where semaglutide is not appropriate. It is not recommended during pregnancy, while breastfeeding, or for those trying to conceive. It is not licensed for people under 18. A personal or family history of certain thyroid tumours, or a history of pancreatitis, requires careful prescriber discussion before any GLP-1 medicine is considered. These are not bureaucratic hurdles, they are the reason a clinical assessment exists.

For women using oral contraception, the current evidence does not show reduced pill effectiveness with semaglutide specifically, though this remains an area where your prescriber will want to review your full medicines list. The NHS England guidance on weight management injections covers the broader picture of what to discuss with a clinician before starting.

Making the decision about treatment

The central question most people arrive at is not purely mechanical, it is personal. Does the weight-loss potential outweigh the side-effect profile for me? Is now the right time? What does a year of weekly injections actually look like in practice?

The most common side effects are gastrointestinal: nausea, loose stools, constipation, reflux, and burping tend to be most noticeable in the first few weeks or after a dose increase, and they settle for most people as the body adjusts. Serious events are uncommon but real, including acute pancreatitis, which prompted an MHRA safety communication in early 2026. Anyone on treatment who develops severe stomach pain spreading to the back should seek urgent medical help.

Cost is another factor. Private treatment is not cheap, and it is worth understanding what a quoted price includes, prescription, clinical review, delivery and aftercare support all vary between providers. Our treatment page shows what is included at nume for a single transparent price, with no subscription and no auto-renewal. There is also a wider page on weight-loss treatment options if you want to compare approaches before deciding.

If you are weighing up whether semaglutide is the right fit for your situation, a good next step is reading how it compares to other options. The page on semaglutide alongside resistance training is one example of how lifestyle choices interact with treatment. When you are ready to talk through the specifics with a clinician, you can check your eligibility through a free consultation, reviewed the same day by a GPhC-registered prescriber, not software.